How GLP-1s Are Rewriting What Consumption Means

Protein was everywhere again at Expo West. In everything from pasta, chips, and water to yogurt, ice cream, and candy. If it had a label, it had a gram count. A much bigger stage than Fancy Food, where we clocked the same trend, the sheer volume at Expo West made one thing undeniable: this isn't a product moment. It's a consumer behavior moment.

Expo West didn't invent the protein trend. Fueled by fitness culture and low-carb diets, protein has been a thing for decades, but the sheer mass of people on GLP-1s pushed protein front and center. 

When appetite lessens, satiety per bite becomes the most important variable in a product's value proposition. Protein delivers it. The show floor was just the industry's collective answer to that demand, thousands of SKUs making the same implicit argument: we're doing more with less.

The brands that will win this aren't the ones that added 20g and updated their packaging. They're the ones who understand why protein is winning and have built their new products around function, texture, and genuine intention rather than a nutrient claim. 

Because what's unfolding isn't just reduced appetite. It's a redistribution of attention, time, reward, and intent. Calories were just the first domino.

The Halo Effect Is Real

The GLP-1 landscape recently gained another structural pillar: an oral pill entering mainstream use. In its first full week on the U.S. market, Novo Nordisk's oral Wegovy pill was prescribed more than 18,000 times, outpacing early uptake for both injectables and rival offerings. A daily pill is cheaper and more accessible than a weekly injection. That means more people entering GLP-1 therapy sooner, and a structural shift in consumption that isn't slowing; it's broadening.

The Grocery Basket Conundrum

Reports indicate that when a primary shopper starts a GLP-1, total household grocery spend drops by roughly 5–6%. Snacks fade. Portions normalize. Produce rises. The user becomes an unintentional nutritional gatekeeper for everyone under the same roof.

The industry's instinct is to read this as a volume problem. It isn't, or at least, not entirely. Households may buy fewer things, but they're often willing to pay more for what survives the cut. Volume brands feel pain first. Brands built on quality, function, or ritual can quietly gain share. The real battleground isn’t less grocery spend, it’s choice.  

Less Food But More Dining

People are eating less. They are not abandoning restaurants.

Dining out often holds steady or increases among GLP-1 users because restaurants solve a new problem: how to eat intentionally without overdoing it. The meal becomes more social, more controlled, more premium, a structure that gives people permission to enjoy food without excess.

What's fading for this group: bread-heavy starters, fried carb-first dishes, redundant sides, "just because" ordering. What's rising: protein-forward starters, small plates that function as entrées, and menus built around clarity and intention.

Apparel: It's Not Just Smaller, It’s Stretchy

Retail is discovering that size curves no longer behave predictably.

Bodies change unevenly. In this kind of diet, waistlines shrink faster than hips. Faces thin before torsos. Consumers cycle through sizes rather than settling on one. This doesn't just disrupt inventory; it creates sustained demand for transitional wardrobes, stretch and adaptive design, tailoring, resale, rental, and modular fits. Brands that sell a fixed silhouette are selling into a moving target. Brands that sell adaptability will outperform.

The Aesthetic Gold Rush

Rapid weight loss creates physical volume gaps, especially in the face and upper body, and that has pulled a massive wave of first-time consumers into aesthetics. But early demand skews corrective, not preventative. Over time, it shifts toward maintenance, regeneration, and prevention.

The long-term winner in this category isn't the brand fixing “Ozempic Face”, it's the brand that owns the preventative and maintenance layer, the topical, ingestible, non-invasive treatments that people use before correction fatigue sets in.

Sensory Rewiring: Flavor Matters, But Differently

GLP-1s diminish desire. 

Sweetness thresholds drop. Legacy sugar levels feel overwhelming. Crunch, bitterness, acid, and savory textures gain importance. Texture starts doing the psychological work that calories once did. Flavor strategies built on excess, on more, bigger, sweeter, richer, are less effective. Those built on contrast, texture, and enhanced flavor are more appealing.

Travel Is Thriving. The Buffet Is Dying.

Buffets, cruises, and volume-driven indulgence are losing appeal. Active trips, wellness-forward stays, and intentional menus are rising. Hotels aren't adding nutritionist-approved menus for optics, they're responding to guests who choose to physically engage in new ways. The hospitality brands that win this shift are the ones offering something more and amenities specifically targeted to this audience.

The Hunger Dividend

Eating less doesn't just change baskets. It changes schedules.

Shorter meals. Fewer snack runs. Less decision fatigue. That time gets re-spent into fitness, grooming, wellness services, and short active experiences. GLP-1s are quietly reallocating discretionary spend away from food and toward services. 

Ozempic Is a Temperance Movement Nobody Voted For

GLP-1s dampen reward pathways beyond food. Alcohol feels less rewarding and people lose their taste for it. Social drinking declines not because of discipline, but because of neurochemistry. Gambling, nicotine, and impulse treats face similar friction.

This isn't moral change. It's chemical. Mid-tier dopamine brands hollow out. Premium, ritualized, or zero-proof products survive not because they're virtuous but because they're subject to diminishing returns.

The Forklift Take

Here's what the Expo West floor didn't show you: a winner.

It showed you a category in motion. Thousands of brands making rational bets on the demands that everyone can read. More protein. More fiber. Better macros. Cleaner labels. All correct. All insufficient on their own.

The brands that make it through this shift aren't the ones who responded fastest; they're the ones who understand the consumer behavioral shift. The “Ozempic effect” isn't about eating less. It's about buying differently, spending differently, and living differently. With oral delivery accelerating adoption across a broader population, the window for figuring out which side of this you're on is getting shorter.

GLP-1s aren't making the consumer pool smaller; they're reducing the market for excess and raising the stakes. Fewer impulses. Less volume. Higher selectivity. More intention. Every product that survives the cut has to earn it, on function, on texture, on relevance, on the specific thing it does that nothing else does as well. Brands built on precision will quietly “inherit the earth.”

The winners are still being built. The question is whether you're building one or watching someone else do it.

We’re here to help.